Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A-Reference-Cited by-同舟云学术

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A

Published:2016-12-10 Issue:4 Volume:101 Page:519-530
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Prueksaritanont T¹²,Tatosian DA¹,Chu X¹,Railkar R³,Evers R¹,Chavez-Eng C¹,Lutz R¹,Zeng W¹,Yabut J¹,Chan GH¹,Cai X¹,Latham AH⁴,Hehman J⁴,Stypinski D⁵,Brejda J⁵,Zhou C⁵,Thornton B⁶,Bateman KP¹,Fraser I¹⁷,Stoch SA⁸

Affiliation:

1. Department of Pharmacokinetics; Pharmacodynamics, and Drug Metabolism, Merck & Co; Kenilworth New Jersey USA

2. Faculty of Pharmaceutical Sciences; Chulalongkorn University; Bangkok Thailand

3. Department of Biostatistics and Research Decision Sciences; Merck & Co; Kenilworth New Jersey USA

4. Department of Pharmaceutical Sciences and Clinical Supply; Merck & Co; Kenilworth New Jersey USA

5. Data Management and Biometrics; Celerion; Lincoln Nebraska USA

6. Department of Translational Pharmacology Clinical Operations; Merck & Co; Kenilworth New Jersey USA

7. Abide Therapeutics; San Diego California USA

8. Department of Translational Pharmacology; Merck & Co; Kenilworth New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.525/fullpdf

Reference47 articles.

1. Membrane transporters in drug development;International Transporter Consortium;Nat. Rev. Drug Discov.,2010

2. Drug-drug interaction studies: regulatory guidance and an industry perspective;Prueksaritanont;AAPS J.,2013

3. In vitro methods to support transporter evaluation in drug discovery and development;Brouwer;Clin. Pharmacol. Ther.,2013

4. Validation of the five-drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug-metabolizing enzymes;Frye;Clin. Pharmacol. Ther.,1997

5. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferases-2, and xanthine oxidase with the “Copperstown cocktail”;Streetman;Clin. Pharmacol. Ther.,2000

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes;Annual Review of Pharmacology and Toxicology;2024-01-23

2. The Effect of BI 730357 (Retinoic Acid‐Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open‐Label, Non‐randomized, 2‐Period Fixed‐Sequence Trial in Healthy Subjects;Clinical Pharmacology in Drug Development;2023-11-13

3. Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects;Clinical Drug Investigation;2023-10-19

4. Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance;Pharmacology & Therapeutics;2023-08

5. Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants;British Journal of Clinical Pharmacology;2023-07-12